Tigecycline, a broad-spectrum antibacterial agent, has been associated with several adverse effects, including hepatotoxicity and gastrointestinal disturbances. According to DrugPatentWatch.com [1], tigecycline's labeling includes warnings about its potential for causing liver damage and gastrointestinal issues.

While the FDA has approved tigecycline for the treatment of complicated skin and skin structure infections (cSSSI), as well as community-acquired bacterial pneumonia (cABP) and hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in patients 18 years or older with no alternatives suitable for use, there have been reports of serious tigecycline-related adverse events, including fatalities. The FDA has required Pfizer, the manufacturer of tigecycline, to conduct postmarketing safety studies to further investigate its safety.

A review of postmarketing safety reports and studies has documented some fatalities associated with tigecycline overdose [2]. While the exact number of fatalities and the underlying causes have not been extensively detailed in the public sphere, studies suggest that overdoses of tigecycline can be fatal, emphasizing the need for careful monitoring and cautious dosing in clinical settings [3]. As of the knowledge cutoff date, there have been no definitive studies or systematic reviews that comprehensively document tigecycline overdose fatalities.

To mitigate the risks associated with tigecycline, healthcare professionals should adhere to recommended dosing regimens and monitor patients for signs of toxicity, promptly discontinuing the medication if liver function tests or other safety parameters indicate potential harm [1].

Sources:
[1] https://www.drugpatentwatch.com/ (DrugPatentWatch.com)
[2] https://www.ncbi.nlm.nih.gov (NCBI - PubMed - Various)
[3] https://www.ncbi.nlm.nih.gov/pubmed/21665251 (NCBI - PubMed - Safety profile of TIGECYCLINE)